China chip stocks fall as US considers allowing Nvidia H200 sales

Chinese chipmakers tumbled after reports the U.S. Trump administration is internally considering allowing NVIDIA to sell its more advanced H200 AI chip in China, a move that could intensify competition and curb demand for local suppliers. Semiconductor Manufacturing International (0981) slid as much as 7%, Hua Hong Semiconductor fell nearly 6%, Cambricon moved down up to 2% before reversing, NAURA rose 2.6%, and the Hang Seng chipmakers index was off ~0.1%; the decision is not imminent and faces competing U.S. legislative pressure such as the bipartisan GAIN AI act. The story highlights policy-driven risk to Chinese semiconductor equities and ongoing geopolitical/regulatory uncertainty that hedge funds should weigh when sizing China/AI hardware exposure.

Analysis

Market structure: Allowing advanced NVIDIA H200 sales into China materially reallocates high-margin AI-inference spend toward foreign GPUs and cloud OEMs (est. 15–25% share shift in AI server spend over 12–18 months), hurting domestic accelerator vendors and foundries that rely on downstream AI design wins. Pricing power shifts to NVIDIA and server integrators (SMCI), pressuring ASPs and gross margins for Chinese fabless names; expect near-term revenue downgrades concentrated in 2–4 Chinese names and localized 5–15% EPS risk for exposed players.

Risk assessment: Tail scenarios include rapid policy reversal (GAIN AI or congressional ban) or reciprocal Chinese restrictions — either could cause >30% moves in individual names; conversely, muted enforcement or delayed approvals could compress realized impact to <10%. Timeline: immediate (days) = sentiment/volatility spike; short-term (weeks–months) = order reallocation and inventory digestion; long-term (1–3 years) = structural market share and capex reallocation. Hidden dependencies: cloud procurement cycles, customs clearance, and Chinese subsidy acceleration can blunt or amplify effects.

Trade implications: Favor long exposure to NVIDIA and US server OEMs that capture Chinese demand, and hedge/short HK-listed Chinese chip plays and related credit. Options: use directional call spreads on NVDA (3–6 month) and buy puts on 0981.HK (3 months) as insurance; baseline portfolio tilts should be sized to 2–4% of NAV per position with tight stop-loss triggers. Catalysts to watch for execution: Commerce announcement, GAIN AI bill votes, major cloud order disclosures.

Contrarian angles: Consensus underestimates China’s policy response — aggressive subsidies/capex could restore domestic competitors within 12–24 months, making current sell-offs partially overdone; historically (post-2018 Huawei restrictions) local vendors recovered via protectionism and scale. Risks to the obvious NVDA-long/China-short trade include logistical delays and phased approval limiting initial shipments; if SMIC or Hua Hong selloffs exceed 20%, consider selective re-entry because downside may be capped by state support.

Key Decisions for Investors

• Establish a 2–3% long NVDA position within 48–72 hours via stock or a 3–6 month call-spread (buy 0.35–0.5 delta calls, sell 5–10% OTM calls) to capture re-rating if approvals proceed; set a tactical take-profit at +25% and stop-loss at -12%.
• Initiate a 2% short position in 0981.HK (SMIC) or buy 3-month puts 5–10% OTM sized to 2% NAV, increasing hedge to 4% NAV if the share price breaks -15% from current levels or if Commerce issues formal approval language without legislative blocking.
• Pair trade: go long SMCI (SMCI) 1–2% vs short 0981.HK 2–3% to capture server/OEM upside and Chinese foundry risk; rebalance after 30–60 days or after major legislative/cabinet announcements.
• Buy a 3-month put on the Hang Seng Tech or a HK chipmakers ETF ~10% OTM sized to 1–1.5% NAV as portfolio insurance; reduce hedge by 50% if Congressional action (GAIN AI) is voted down or official Commerce memo explicitly limits H200 scope.
• If SMIC/Hua Hong decline >20% intraday, deploy a 0.5–1% contrarian long for mean-reversion with hard stop at -15% and target +40% within 12 months, because state support and capex plans likely create asymmetric recovery potential.